{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:40:50Z","timestamp":1792636850102,"version":"4.5.0"},"reference-count":328,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaad.2023.02.072","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T01:06:05Z","timestamp":1690506365000},"page":"885-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis"],"prefix":"10.1016","volume":"90","author":[{"given":"Brian M.","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Kwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Bolognia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.02.072_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib2","series-title":"Dermatology","first-page":"348","article-title":"Drug reactions","author":"Valeyrie-Allanore","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.072_bib3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.1984.03340320048027","article-title":"Landmark article Sept 17, 1938: sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam","volume":"251","author":"Merritt","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.02.072_bib4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM195006082422304","article-title":"Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis","volume":"242","author":"Chaiken","year":"1950","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: dress)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2023.02.072_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/biomedicines10050999","article-title":"Drug reaction with eosinophilia and systemic symptoms (DReSS)\/Drug-Induced hypersensitivity syndrome (DiHS)-Readdressing the DReSS","volume":"10","author":"Stirton","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaad.2023.02.072_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","article-title":"Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan","volume":"22","author":"Chiou","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib9","article-title":"A Multi-Center, Retrospective Analysis of the Diagnosis, Management, and Outcomes Among Patients With Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS). Abstract\/presentation at the","author":"Emge","year":"2022","journal-title":"Medical Dermatology Society meeting"},{"key":"10.1016\/j.jaad.2023.02.072_bib10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jaad.2020.03.081","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pde.14044","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature","volume":"37","author":"Metterle","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/pde.14446","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature, with a focus on relapsing cases","volume":"38","author":"Afiouni","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib13","first-page":"1187","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.02.072_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MD.0b013e3181a4d1a1","article-title":"Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients","volume":"88","author":"Ben M'rad","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2023.02.072_bib15","series-title":"Litt's Drug Eruption and Reaction Database","author":"Litt","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.072_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.artd.2019.04.005","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome after total knee arthroplasty infection and placement of antibiotic spacer","volume":"5","author":"Harper","year":"2019","journal-title":"Arthroplast Today"},{"key":"10.1016\/j.jaad.2023.02.072_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaip.2020.09.040","article-title":"DRESS syndrome induced by antibiotic-loaded bone cements and a diagnostic algorithm for related delayed-type hypersensitivity reactions","volume":"9","author":"Chiang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib18","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","article-title":"Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and drug administration adverse event reporting system","volume":"9","author":"Bluestein","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2023.02.072_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-015-2870-0","article-title":"Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib21","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/jdv.13892","article-title":"Nivolumab therapy before vemurafenib administration induces a severe skin rash","volume":"31","author":"Imafuku","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib23","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/CMR.0000000000000472","article-title":"Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma","volume":"28","author":"Lamiaux","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib25","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and drug administration adverse event reporting system","volume":"24","author":"Raschi","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.jaad.2023.02.072_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clindermatol.2019.10.015","article-title":"The life-threatening eruptions of immune checkpoint inhibitor therapy","volume":"38","author":"Coleman","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/toxsci\/kfab144","article-title":"Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity","volume":"186","author":"Hammond","year":"2022","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib29","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s00520-021-06543-9","article-title":"Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review","volume":"30","author":"Maloney","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2023.02.072_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaad.2018.07.029","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: a series of 11 cases","volume":"80","author":"Br\u00e9geon","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0475-y","article-title":"Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF\/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series","volume":"7","author":"Naqash","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2023.02.072_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1574884715666200628113508","article-title":"Vemurafenib induced drug reaction with eosinophilia and systemic symptoms (DRESS): a disproportionality analysis in FAERS Database","volume":"16","author":"Neha","year":"2021","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/or.2020.7911","article-title":"Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)","volume":"45","author":"Coleman","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1539\/joh.48.417","article-title":"Human herpesvirus 6 reactivation in trichloroethylene-exposed workers suffering from generalized skin disorders accompanied by hepatic dysfunction","volume":"48","author":"Huang","year":"2006","journal-title":"J Occup Health"},{"key":"10.1016\/j.jaad.2023.02.072_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000290775","article-title":"Occupational trichloroethylene hypersensitivity syndrome with human herpesvirus-6 and cytomegalovirus reactivation","volume":"221","author":"Watanabe","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1346-8138.2010.01155.x","article-title":"Hypersensitivity syndrome due to trichloroethylene exposure: a severe generalized skin reaction resembling drug-induced hypersensitivity syndrome","volume":"38","author":"Watanabe","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jdermsci.2013.07.003","article-title":"Occupational trichloroethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes","volume":"72","author":"Kamijima","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib38","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1398-9995.2008.01689.x","article-title":"DRESS syndrome induced by sodium meglumine ioxitalamate","volume":"63","author":"Belhadjali","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib39","first-page":"56","article-title":"DRESS syndrome involving 2 unrelated substances: imipenem and iodinated contrast media","volume":"23","author":"Macias","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ccr3.513","article-title":"Systemic hypersensitivity reaction to Omnipaque radiocontrast medium: a case of mini-DRESS","volume":"4","author":"George","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ced.13991","article-title":"Contrast media and cutaneous reactions. Part 2: delayed hypersensitivity reactions to iodinated contrast media","volume":"44","author":"Tasker","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib42","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.jaip.2021.02.060","article-title":"DRESS and AGEP reactions to iodinated contrast media: a French case series","volume":"9","author":"Soria","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.18176\/jiaci.0742","article-title":"DRESS syndrome with gadolinium contrast media in a 13-year-old boy","volume":"32","author":"Macias-Iglesias","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib44","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/imj.12012","article-title":"Drug reaction with eosinophilia and systemic symptoms associated with H1N1 vaccination","volume":"42","author":"Hewitt","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2023.02.072_bib45","article-title":"DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine","volume":"2016","author":"Solak","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cmi.2021.05.023","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19","volume":"27","author":"Ramirez","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaad.2023.02.072_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102337","article-title":"Does sensitization by SARS-CoV-2 immune complexes trigger DRESS syndrome?","volume":"26","author":"Cruz","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jaad.2023.02.072_bib48","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1111\/1346-8138.16541","article-title":"Overlapping acute generalized exanthematous pustulosis drug reaction with eosinophilia and systemic symptoms induced by a second dose of the Moderna COVID-19 vaccine","volume":"49","author":"Ikeda","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/1346-8138.16347","article-title":"Three cases of drug-induced hypersensitivity syndrome associated with mRNA-based coronavirus disease 2019 vaccines","volume":"49","author":"Korekawa","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.11.028","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome following vaccination with the AstraZeneca COVID-19 vaccine","volume":"20","author":"O'Connor","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clindermatol.2022.02.018","article-title":"A definite case of drug reaction with eosinophilia and systemic symptoms (DRESS) induced by administration of the Pfizer\/BioNTech BNT162b2 vaccine for SARS-CoV2","volume":"40","author":"Schroeder","year":"2022","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib52","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib53","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1067\/mai.2003.1507","article-title":"Characterization of drug-specific T cells in lamotrigine hypersensitivity","volume":"111","author":"Naisbitt","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib54","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib55","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1365-2133.1998.02559.x","article-title":"Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome","volume":"139","author":"Choquet-Kastylevsky","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib56","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type 1 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jaad.2023.02.072_bib57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2133.2003.05368.x","article-title":"Carbamazepine-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction","volume":"149","author":"Aihara","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","article-title":"An essential role for Scurfin in CD4+CD25+ T regulatory cells","volume":"4","author":"Khattri","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib59","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1442-200x.2005.02143.x","article-title":"Different patterns of cytokines, ECP and immunoglobulin profiles at two adverse drug reactions in a patient","volume":"47","author":"Aihara","year":"2005","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000084765","article-title":"Drug-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and increase in serum IgE level","volume":"210","author":"Nakashima","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2023.02.072_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaad.2006.02.050","article-title":"Hypogammaglobulinemia as an early sign of drug-induced hypersensitivity syndrome","volume":"55","author":"Kano","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2230.2005.01913.x","article-title":"A case of drug-induced hypersensitivity syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus","volume":"31","author":"Takahashi","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2023.02.072_bib64","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1386-6532(06)70019-1","article-title":"Human herpesvirus 6 reactivation and inflammatory cytokine production in patients with drug-induced hypersensitivity syndrome","volume":"37","author":"Yoshikawa","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jaad.2023.02.072_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jdermsci.2007.05.013","article-title":"T cell populations propagating in the peripheral blood of patients with drug eruptions","volume":"48","author":"Nishio","year":"2007","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib66","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2023.02.072_bib67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2008.08750.x","article-title":"A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome","volume":"159","author":"Tohyama","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.autrev.2009.02.029","article-title":"Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes","volume":"8","author":"Aota","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2023.02.072_bib69","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib70","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2230.2010.03820.x","article-title":"Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions","volume":"35","author":"Hirahara","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib71","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaci.2010.06.004","article-title":"Fluctuation of blood and skin plasmacytoid dendritic cells in drug-induced hypersensitivity syndrome","volume":"126","author":"Sugita","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib72","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/exd.12027","article-title":"IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation","volume":"21","author":"Balato","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jdermsci.2011.12.002","article-title":"The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity","volume":"65","author":"Hanafusa","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-3038.2012.01268.x","article-title":"The association between DRESS and the diminished numbers of peripheral B lymphocytes and natural killer cells","volume":"23","author":"Yazicioglu","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"Ogawa","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib76","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bjd.13162","article-title":"The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"171","author":"Fujita","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib77","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ced.12246","article-title":"Increased ratio of FoxP3+ regulatory T cells\/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms","volume":"39","author":"Morito","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.12948","article-title":"Elevated serum thymus and activation-regulated chemokine (TARC\/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DIHS)","volume":"171","author":"Ogawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2014.01.007","article-title":"TNF-alpha as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"74","author":"Uno","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/all.12602","article-title":"Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study","volume":"70","author":"Chen","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib81","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells Possess Preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib82","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2023.02.072_bib83","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jaad.2015.11.031","article-title":"Plasmacytoid dendritic cells (pDCs) and regulatory T (Treg) cells may be the key to viral reactivation in drug-induced hypersensitivity syndrome (DIHS)","volume":"74","author":"Chen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jdermsci.2015.11.002","article-title":"Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy","volume":"81","author":"Hashizume","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib85","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaip.2016.10.009","article-title":"Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: an immunohistochemical study","volume":"5","author":"Hansel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fmed.2017.00136","article-title":"Regulation of eosinophil and group 2 innate lymphoid cell trafficking in asthma","volume":"4","author":"Larose","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib87","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.iac.2017.07.007","article-title":"Severe delayed drug reactions: role of genetics and viral infections","volume":"37","author":"Pavlos","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaad.2023.02.072_bib88","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaip.2016.11.027","article-title":"Virus reactivation in drug reaction with eosinophilia and systemic symptoms (dress) results from a Strong drug-specific immune response","volume":"5","author":"Roujeau","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib89","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.alit.2016.06.003","article-title":"Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions","volume":"66","author":"Komatsu-Fujii","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fmed.2017.00179","article-title":"New insights into drug reaction with eosinophilia and systemic symptoms Pathophysiology","volume":"4","author":"Musette","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global Perspective on the science and art of current Practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000475546","article-title":"Skin-homing IL-13-producing T cells expand in the circulation of patients with drug rash with eosinophilia and systemic symptoms","volume":"233","author":"Teraki","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcmgh.2017.01.005","article-title":"Thymic stromal lymphopoietin: to cut a long story short","volume":"3","author":"Tsilingiri","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib94","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjd.14839","article-title":"Drug-specific CD4(+) T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome","volume":"176","author":"Ye","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib95","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bjd.16132","article-title":"Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome","volume":"178","author":"Nakamura-Nishimura","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib96","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/cea.13252","article-title":"Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions","volume":"48","author":"Ushigome","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib97","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","article-title":"Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome","volume":"139","author":"Tsai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib98","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/1346-8138.15548","article-title":"Parallel changes in serum thymus and activation-regulated chemokine levels in response to flare-ups in drug-induced hypersensitivity syndrome","volume":"47","author":"Kanatani","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib99","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.5415\/apallergy.2020.10.e2","article-title":"Altered T cell and monocyte subsets in prolonged immune reconstitution inflammatory syndrome related with DRESS (drug reaction with eosinophilia and systemic symptoms)","volume":"10","author":"Kang","year":"2020","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib100","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bjd.18942","article-title":"The interferon-\u03b3-induced protein 10\/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms","volume":"183","author":"Yang","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib101","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.aller.2019.02.003","article-title":"Serum soluble Fas ligand levels and peripheral blood lymphocyte subsets in patients with drug-induced maculopapular rashes, dress, and viral exanthemas","volume":"48","author":"Yazicioglu","year":"2020","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.jaad.2023.02.072_bib102","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jaci.2021.03.015","article-title":"Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s","volume":"147","author":"Bartemes","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib103","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1111\/1346-8138.15967","article-title":"Increased CD30(+) cells in skin lesions of drug-induced hypersensitivity syndrome: are type-2 innate lymphoid cells present?","volume":"48","author":"Hashizume","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib104","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1111\/1346-8138.16341","article-title":"Sequential screening of biomarkers in a case of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms occurring with virus reactivation and autoimmune disease","volume":"49","author":"Lee","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.14074","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients","volume":"45","author":"Sueki","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.alit.2021.12.002","article-title":"Drug allergy and non-HIV immune reconstitution inflammatory syndrome","volume":"71","author":"Sueki","year":"2022","journal-title":"Allergol Int"},{"issue":"Pt 6","key":"10.1016\/j.jaad.2023.02.072_bib107","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1099\/0022-1317-76-6-1409","article-title":"Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication","volume":"76","author":"Kuntz-Simon","year":"1995","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jaad.2023.02.072_bib108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1684\/ejd.2010.0821","article-title":"Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in\u00a0vitro","volume":"20","author":"Mardivirin","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/00015550410024094","article-title":"Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells","volume":"85","author":"Hashizume","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib110","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","article-title":"Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome","volume":"157","author":"Tohyama","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib111","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2340\/00015555-2867","article-title":"Clinical, viral and genetic characteristics of drug reaction with eosinophilia and systemic symptoms (DRESS) in shanghai, China","volume":"98","author":"Wu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib112","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jid.2021.11.008","article-title":"Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification","volume":"142","author":"Mizukawa","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib113","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2133.1997.tb03795.x","article-title":"Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome","volume":"137","author":"Descamps","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib114","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archderm.134.9.1108","article-title":"Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome","volume":"134","author":"Suzuki","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib115","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.134.9.1113","article-title":"Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6","volume":"134","author":"Tohyama","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib116","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.pnpbp.2006.01.021","article-title":"Case reports and literature review: the association between reactivation of human herpes virus-6 and peripheral white blood cell count in patients with carbamazepine-induced hypersensitivity syndrome","volume":"30","author":"Matsuda","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jaad.2023.02.072_bib117","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1365-4632.2009.04410.x","article-title":"Withdrawal of the culprit drug induces reactivation of human herpesvirus 6 in drug-induced hypersensitivity syndrome","volume":"49","author":"Teraki","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib118","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamadermatol.2013.2018","article-title":"Saliva polymerase chain reaction assay for detection and follow-up of herpesvirus reactivation in patients with drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"149","author":"Descamps","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib119","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jcv.2014.08.025","article-title":"Evidence for human herpesvirus-6B infection of regulatory T-cells in acute systemic lymphadenitis in an immunocompetent adult with the drug reaction with eosinophilia and systemic symptoms syndrome: a case report","volume":"61","author":"Mine","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jaad.2023.02.072_bib120","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2340\/00015555-2925","article-title":"Up-regulation of human herpesvirus 6B-derived microRNAs in the serum of patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"98","author":"Miyashita","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib121","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/all.12138","article-title":"Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy","volume":"68","author":"Hashizume","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib122","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2009.09280.x","article-title":"Emergence of circulating monomyeloid precursors predicts reactivation of human herpesvirus-6 in drug-induced hypersensitivity syndrome","volume":"161","author":"Hashizume","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib123","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2340\/00015555-2791","article-title":"Predominant contribution of CD4 T cells to human herpesvirus 6 (HHV-6) load in the peripheral blood of patients with drug-induced hypersensitivity syndrome and persistent HHV-6 infection","volume":"98","author":"Miyagawa","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2016.05.001","article-title":"Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"83","author":"Miyagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib125","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3465","article-title":"Correlation between expression of CD134, a human herpesvirus 6 cellular receptor, on CD4+ T cells and Th2-type immune responses in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"100","author":"Miyagawa","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib126","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2133.2006.07332.x","article-title":"Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome","volume":"155","author":"Seishima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib127","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.jaad.2023.02.072_bib128","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1468-3083.2012.04560.x","article-title":"Deep venous thrombosis associated with cytomegalovirus reactivation in drug-induced hypersensitivity syndrome","volume":"27","author":"Hashizume","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5021\/ad.2018.30.1.71","article-title":"Drug reaction with eosinophilia and systemic symptoms associated with reactivation of epstein-Barr virus and\/or cytomegalovirus leading to hemophagocytic syndrome in one of two patients","volume":"30","author":"Liang","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.11622\/smedj.2018016","article-title":"Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms","volume":"59","author":"Wong","year":"2018","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jaad.2023.02.072_bib131","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1346-8138.2005.tb00762.x","article-title":"Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation","volume":"32","author":"Sekiguchi","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib132","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1046\/j.1365-2133.2003.05330.x","article-title":"Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection","volume":"148","author":"Descamps","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib133","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1346-8138.16415","article-title":"Severe graft-versus-host disease-like enterocolitis accompanied with cytomegalovirus-reactivation in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"49","author":"Takamiyagi","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib134","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3748\/wjg.v16.i26.3339","article-title":"Isolated ileal perforation due to cytomegalovirus reactivation during management of terbinafine hypersensitivity","volume":"16","author":"Sano","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2023.02.072_bib135","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archdermatol.2009.195","article-title":"Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome","volume":"145","author":"Asano","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib136","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2169\/internalmedicine.40.331","article-title":"Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia","volume":"40","author":"Arakawa","year":"2001","journal-title":"Intern Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib137","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1346-8138.2005.tb00885.x","article-title":"Drug-induced hypersensitivity syndrome associated with human herpesvirus 6 and cytomegalovirus reactivation","volume":"32","author":"Komura","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib138","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00198-015-3384-7","article-title":"A fatal case of DRESS induced by strontium ranelate associated with HHV-7 reactivation","volume":"27","author":"Drago","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib139","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jmv.20295","article-title":"Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses","volume":"75","author":"Mitani","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2023.02.072_bib140","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-4632.2009.04441.x","article-title":"Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol","volume":"49","author":"Hamaguchi","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib141","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1346-8138.12012","article-title":"Case of drug-induced hypersensitivity syndrome with multiple skin ulcers caused by herpes simplex virus reactivation","volume":"40","author":"Morita","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib142","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1684\/ejd.2017.3117","article-title":"Herpes simplex virus reactivation: is it common or rare in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms?","volume":"27","author":"Kurata","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib143","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-1317","article-title":"Herpes zoster in patients with drug-induced hypersensitivity syndrome\/DRESS","volume":"92","author":"Kano","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib144","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2340\/00015555-1993","article-title":"Drug-induced hypersensitivity syndrome in association with varicella","volume":"95","author":"Tsutsumi","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.907345","article-title":"Case report: successful treatment of Kaposi's sarcoma with anlotinib in an HIV-negative patient after the treatment of drug reaction with eosinophilia and systemic symptoms accessory tragus","volume":"9","author":"Lin","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib146","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2332\/allergolint.C-06-49","article-title":"Drug-induced hypersensitivity syndrome associated with a marked increase in anti-paramyxovirus antibody titers in a scleroderma patient","volume":"56","author":"Naniwa","year":"2007","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib147","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jdcr.2018.03.024","article-title":"Reticular rash in drug reaction with eosinophilia and systemic symptoms syndrome: a clue to parvovirus B19 reactivation?","volume":"4","author":"Cura","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib148","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1507\/endocrj.EJ17-0249","article-title":"A case report of fulminant type 1 diabetes mellitus associated with drug-induced hypersensitivity syndrome in an elderly patient with coxsackie B4 virus infection and human leukocyte antigen-A24 haplotype","volume":"65","author":"Takeno","year":"2018","journal-title":"Endocr J"},{"key":"10.1016\/j.jaad.2023.02.072_bib149","first-page":"277","article-title":"DRESS syndrome associated with influenza virus","volume":"32","author":"Girijala","year":"2019","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.jaad.2023.02.072_bib150","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16838","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19","volume":"34","author":"Herman","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000510706","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with mycoplasma pneumoniae infection","volume":"12","author":"Shalom","year":"2020","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244063","article-title":"Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) with concomitant acute chikungunya virus infection: possible role of new viral trigger","volume":"14","author":"Sil","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib153","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bjd.21706","article-title":"Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system","volume":"187","author":"Cucka","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib154","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1289\/ehp.10325","article-title":"HLA-B\u22171301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China","volume":"115","author":"Li","year":"2007","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jaad.2023.02.072_bib155","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-4632.2010.04481.x","article-title":"Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia","volume":"49","author":"Ding","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib156","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaad.2023.02.072_bib157","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A\u22173101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaad.2023.02.072_bib158","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5694\/mja12.10477","article-title":"Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele","volume":"197","author":"Harding","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaad.2023.02.072_bib159","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","article-title":"HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population","volume":"39","author":"Niihara","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib161","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B\u221758:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Goncalo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib162","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tube.2012.10.010","article-title":"Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen","volume":"93","author":"Kim","year":"2013","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jaad.2023.02.072_bib163","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B\u221713:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib164","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2013.10.003","article-title":"Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations","volume":"73","author":"Hsiao","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib165","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/pgs.15.21","article-title":"Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review","volume":"16","author":"Jarjour","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2023.02.072_bib166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/jidsymp.2015.6","article-title":"Research on susceptible genes and immunological pathogenesis of cutaneous adverse drug reactions in Chinese hans","volume":"17","author":"Yang","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2023.02.072_bib167","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","article-title":"Impact of the HLA-B(\u2217)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions","volume":"136","author":"Ng","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib168","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (\u2217) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib169","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B\u221715:13 and HLA-B\u221715:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaad.2023.02.072_bib170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmpt-2016-0025","article-title":"An update on HLA alleles associated with adverse drug reactions","volume":"32","author":"Fricke-Galindo","year":"2017","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib171","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","article-title":"Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population","volume":"115","author":"Ram\u00edrez","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib172","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaip.2016.10.008","article-title":"HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin\/tazobactam","volume":"5","author":"Rutkowski","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib173","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B\u221713: 01 allele in the Thai population","volume":"27","author":"Tempark","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaad.2023.02.072_bib174","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cix096","article-title":"Association of the HLA-B\u221753:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with Raltegravir","volume":"64","author":"Thomas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2023.02.072_bib175","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The function of HLA-B\u221713:01 involved in the Pathomechanism of dapsone-induced severe cutaneous adverse reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib176","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib177","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2780272","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib178","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib179","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/bcp.14025","article-title":"High and variable population prevalence of HLA-B\u221756:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms","volume":"85","author":"Somogyi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib180","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9\u22173 as predictors of phenytoin hypersensitivity in east asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib181","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106321","article-title":"Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children","volume":"162","author":"Manuyakorn","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib183","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A\u221711:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients","volume":"140","author":"Nakamura","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib184","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.4979","article-title":"Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population","volume":"29","author":"Sukasem","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2023.02.072_bib185","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of Co-Trimoxazole-Induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib186","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/jpm11080737","article-title":"Association of HLA-B\u221751:01, HLA-B\u221755:01, CYP2C9\u22173, and phenytoin-induced cutaneous adverse drug reactions in the south Indian Tamil population","volume":"11","author":"John","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib187","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/ph14111077","article-title":"A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and Precision medicine","volume":"11","author":"Kloypan","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jaad.2023.02.072_bib188","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41397-021-00247-3","article-title":"Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis","volume":"21","author":"Sukasem","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaad.2023.02.072_bib189","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/pgs-2021-0156","article-title":"Allopurinol-induced severe cutaneous adverse reactions in Vietnamese: the role of HLA alleles and other risk factors","volume":"23","author":"Ha Pham","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2023.02.072_bib190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1\u221715 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.02.072_bib191","series-title":"Medical Genetics Summaries","article-title":"Allopurinol therapy and HLA-B\u221758:01 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.jaad.2023.02.072_bib192","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ACI.0000000000000754","article-title":"Role of pharmacogenomics in T-cell hypersensitivity drug reactions","volume":"21","author":"Hertzman","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib193","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1038\/srep09913","article-title":"Association of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome","volume":"5","author":"Niu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib194","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaad.2023.02.072_bib195","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jdv.12130","article-title":"Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"28","author":"Barbaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib196","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.02.072_bib197","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0702453","article-title":"Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity","volume":"126","author":"Naisbitt","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib198","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jaip.2019.05.034","article-title":"Sulfonamide hypersensitivity: fact and fiction","volume":"7","author":"Khan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib199","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib200","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib201","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"38","author":"Cardones","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib203","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2340\/00015555-1152","article-title":"Multiple follicular pustules as an atypical cutaneous manifestation of drug-induced hypersensitivity syndrome","volume":"91","author":"Ueharaguchi","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib204","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2013.07.046","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome and toxic epidermal necrolysis: an uncommon confounding oral mucosal overlap","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib205","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.14200","article-title":"Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"174","author":"Kurata","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/ijd.IJD_19_17","article-title":"Erythema gyratum repens as a manifestation of drug reaction with eosinophilia and systemic symptoms","volume":"64","author":"Sasidharanpillai","year":"2019","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib207","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/jdv.18100","article-title":"Skin manifestations and clinical features of drug reaction with eosinophilia and systemic symptoms: a retrospective multicentre study of 125 patients","volume":"36","author":"Lee","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib208","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1346-8138.2010.01086.x","article-title":"Possible association of vascular endothelial growth factor with the development of edema in drug-induced hypersensitivity syndrome","volume":"38","author":"Hirakawa","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib209","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2021.04.020","article-title":"Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: facial edema aligns to the severe phenotype","volume":"85","author":"Momen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib210","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1111\/jdv.18270","article-title":"Oblique earlobe crease as a novel physical examination finding in drug reaction with eosinophilia and systemic symptoms: a retrospective study","volume":"36","author":"Gilkey","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib211","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jaad.2013.06.052","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome: a picture is worth a thousand words","volume":"69","author":"Rosenbach","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib212","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2023.02.072_bib213","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4103\/0253-7613.169580","article-title":"Drug reaction with eosinophilia and systemic symptoms without skin rash","volume":"47","author":"Sasidharanpillai","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib214","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/ijd.15196","article-title":"Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review","volume":"60","author":"Yang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28657","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS)-associated hemophagocytic lymphohistiocytosis (HLH), an important and underrecognized HLH mimic: a case report","volume":"68","author":"Carter Febres","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2023.02.072_bib216","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/ced.14572","article-title":"Drug rash with eosinophilia and systemic symptoms complicated by haemophagocytic lymphohistiocytosis: is screening required?","volume":"46","author":"Hussain","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib217","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ajh.26346","article-title":"Hematologic findings in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"96","author":"Pukhalskaya","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2023.02.072_bib218","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jaad.2018.10.064","article-title":"Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms","volume":"80","author":"Dorrell","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib219","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4322\/acr.2012.029","article-title":"Hepatic necrosis associated with drug-induced hypersensitivity syndrome","volume":"2","author":"de Campos","year":"2012","journal-title":"Autops Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/imj.13734","article-title":"Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals","volume":"48","author":"Fang","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2023.02.072_bib221","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2174\/1381612825666191107161912","article-title":"Drug-induced liver injury associated with severe cutaneous hypersensitivity reactions: a complex entity in need of a multidisciplinary approach","volume":"25","author":"Sanabria-Cabrera","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaad.2023.02.072_bib222","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/liv.14990","article-title":"Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan","volume":"41","author":"Huang","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib223","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1665-2681(19)31817-4","article-title":"Dress syndrome and fulminant hepatic failure induced by lamotrigine","volume":"8","author":"Amante","year":"2009","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib224","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/TP.0000000000001655","article-title":"Acute liver failure\/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors","volume":"101","author":"Ichai","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2023.02.072_bib225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10067-012-2152-8","article-title":"Leflunomide-induced DRESS syndrome with renal involvement and vasculitis","volume":"32","author":"Pinto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib226","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.iac.2009.04.007","article-title":"The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug","volume":"29","author":"Kano","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaad.2023.02.072_bib227","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.mcna.2010.03.004","article-title":"Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome","volume":"94","author":"Kano","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jaad.2023.02.072_bib228","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/ijd.13667","article-title":"Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea","volume":"56","author":"Lee","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib229","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7863815","article-title":"Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"2019","author":"Taweesedt","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib230","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.radcr.2020.08.037","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) with severe and atypical lung involvement","volume":"15","author":"Guerrero Gomez","year":"2020","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib231","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4103\/0019-5154.91850","article-title":"Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum","volume":"56","author":"Giri","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib232","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5582\/ddt.2019.01045","article-title":"A case of drug-induced hypersensitivity syndrome induced by salazosulfapyridine combined with SIADH caused by interstitial pneumonia","volume":"13","author":"Morinaga","year":"2019","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib233","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2710.2008.00991.x","article-title":"Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome","volume":"34","author":"Zhu","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2023.02.072_bib234","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ijd.14174","article-title":"Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement","volume":"57","author":"Intarasupht","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.12659\/AJCR.909569","article-title":"Myocarditis associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and review of the literature","volume":"19","author":"Morikawa","year":"2018","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib236","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/jcm11030704","article-title":"\u201cHeart in DRESS\u201d: cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: a systematic review","volume":"11","author":"Radovanovic","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib237","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","article-title":"Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis","volume":"62","author":"Shaughnessy","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib238","first-page":"yty100","article-title":"Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: a case report","volume":"2","author":"Hagiwara","year":"2018","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib239","first-page":"29","article-title":"Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases","volume":"24","author":"Koenig","year":"2022","journal-title":"Neuropsychopharmacol Hung"},{"key":"10.1016\/j.jaad.2023.02.072_bib240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2230.2007.02645.x","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone associated with limbic encephalitis in a patient with drug-induced hypersensitivity syndrome","volume":"33","author":"Sakuma","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib241","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/bjd.12169","article-title":"Thyroid dysfunction in drug reaction with eosinophilia and systemic symptoms (DRESS): an unusual manifestation of systemic drug hypersensitivity","volume":"168","author":"Cookson","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib242","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1346-8138.12028","article-title":"Pustular-type drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms due to carbamazepine with systemic muscle involvement","volume":"40","author":"Matsuda","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib243","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2169\/internalmedicine.55.6035","article-title":"Autoimmune limbic encephalitis and syndrome of inappropriate antidiuretic hormone secretion associated with lamotrigine-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"55","author":"Ozisik","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib244","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.anai.2017.03.007","article-title":"Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome","volume":"118","author":"Massey","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib245","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/jcm10184287","article-title":"Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of the literature","volume":"10","author":"Jevtic","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib246","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/ced.15229","article-title":"Eosinophilic infiltration of oesophagus following carbamazepine-induced drug reaction with eosinophilia and systemic symptoms: an under-reported sequel?","volume":"47","author":"Greenish","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib247","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/09273948.2020.1797111","article-title":"Bilateral marginal corneal infiltrates: a novel ocular manifestation of DRESS syndrome","volume":"30","author":"Vela","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jaad.2023.02.072_bib248","first-page":"e162","article-title":"Drug reaction with eosinophilia and systemic symptoms in children: a prospective study","volume":"33","author":"Sasidharanpillai","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib249","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaip.2016.04.026","article-title":"A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions","volume":"4","author":"Trubiano","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib250","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pds.4774","article-title":"Variation of clinical manifestations according to culprit drugs in DRESS syndrome","volume":"28","author":"Sim","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2023.02.072_bib251","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jaad.2020.03.019","article-title":"Drug reaction with eosinophilia and systemic symptoms within 1 week of exposure to the drug","volume":"83","author":"Sasidharanpillai","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib252","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","article-title":"Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study","volume":"82","author":"Soria","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib253","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/jdv.17631","article-title":"Specific features of amoxicillin-associated drug reaction with eosinophilia and systemic symptoms syndrome: a nationwide study","volume":"35","author":"Largeau","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib254","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaip.2021.07.025","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): series of 49 French pediatric cases","volume":"10","author":"Bedouelle","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2340\/00015555-1222","article-title":"Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms","volume":"92","author":"Wongkitisophon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib256","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4103\/0366-6999.204104","article-title":"Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade","volume":"130","author":"Wang","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaad.2023.02.072_bib257","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/dtb.2021.235803rep","article-title":"Republished: case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure","volume":"59","author":"Winward","year":"2021","journal-title":"Drug Ther Bull"},{"key":"10.1016\/j.jaad.2023.02.072_bib258","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1468-3083.2012.04547.x","article-title":"Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids","volume":"27","author":"Uhara","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib259","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamadermatol.2013.6698","article-title":"Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features","volume":"150","author":"Tetart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib260","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/09564624221103743","article-title":"Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia","volume":"33","author":"Chua","year":"2022","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jaad.2023.02.072_bib261","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/bjd.13079","article-title":"Drug reaction with eosinophilia and systemic symptoms, or virus reactivation with eosinophilia and systemic symptoms as a manifestation of immune reconstitution inflammatory syndrome in a patient with HIV?","volume":"171","author":"Almudimeegh","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib262","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2133.2007.07784.x","article-title":"Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity\u00a0syndrome","volume":"156","author":"Kano","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib263","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2230.2008.02823.x","article-title":"Drug rash with eosinophilia and systemic symptoms and graft-versus-host disease developing sequentially in a patient","volume":"34","author":"Natkunarajah","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib264","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/bmt.2010.324","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant","volume":"46","author":"Lopez-Anglada","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2023.02.072_bib265","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/1756-185X.13004","article-title":"Methotrexate-induced pancytopenia: a case series of 46 patients","volume":"20","author":"Ajmani","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaad.2023.02.072_bib266","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.12783","article-title":"Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"170","author":"Chi","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib267","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib268","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/ijd.13126","article-title":"Adverse cutaneous drug reactions in a single quaternary referral hospital","volume":"55","author":"Botelho","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib269","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/jdv.13832","article-title":"Comparative histological analysis of drug-induced maculopapular exanthema and DRESS","volume":"30","author":"Skowron","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib270","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/ijd.13350","article-title":"Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression","volume":"55","author":"Weinborn","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib271","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6928363","article-title":"Immunohistopathological findings of severe cutaneous adverse drug reactions","volume":"2017","author":"Orime","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib272","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/DAD.0b013e3181a18d64","article-title":"Drug-induced hypersensitivity syndrome with superficial granulomatous dermatitis--a novel finding","volume":"31","author":"Fernando","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2023.02.072_bib273","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/DAD.0000000000000439","article-title":"Histopathology of the exanthema in DRESS is not specific but may indicate severity of systemic involvement","volume":"38","author":"Gon\u00e7alo","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2023.02.072_bib274","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.5858\/arpa.2021-0087-OA","article-title":"Morphologic spectrum of lymphadenopathy in drug reaction with eosinophilia and systemic symptoms syndrome","volume":"146","author":"Chen","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","article-title":"Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients","volume":"63","author":"Ang","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib276","article-title":"DRESS syndrome-associated acute necrotizing eosinophilic myocarditis with giant cells","volume":"2018","author":"Kowtoniuk","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib277","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2015.02.1130","article-title":"Liver injury in patients with DRESS: a clinical study of 72 cases","volume":"72","author":"Lin","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib278","doi-asserted-by":"crossref","first-page":"705","DOI":"10.12998\/wjcc.v7.i6.705","article-title":"Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome","volume":"7","author":"Martinez-Cabriales","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaad.2023.02.072_bib279","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyriere","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib280","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","article-title":"Characteristics of liver injury in drug-induced systemic hypersensitivity reactions","volume":"69","author":"Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib281","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jceh.2018.06.423","article-title":"2. Drug-induced liver injury with hypersensitivity features\/drug reaction with eosinophilia and systemic symptoms (DRESS): a single center experience of 38 cases","volume":"8","author":"Kumar","year":"2018","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib282","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib283","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ced.12682","article-title":"Drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome: clinical features of 27 patients","volume":"40","author":"Avancini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib284","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.alit.2016.09.003","article-title":"Drug-induced hypersensitivity syndrome in Japan in the past 10 years based on data from the relief system of the Pharmaceuticals and Medical Devices Agency","volume":"66","author":"Kinoshita","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib285","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3349\/ymj.2019.60.2.208","article-title":"Analysis of individual case safety reports of severe cutaneous adverse reactions in Korea","volume":"60","author":"Kang","year":"2019","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaad.2023.02.072_bib286","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1111\/bcp.15354","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a tertiary care centre retrospective study","volume":"88","author":"Del Pozzo-Maga\u00f1a","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib289","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib290","first-page":"124","article-title":"Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome","volume":"21","author":"Ikari","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib291","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13601-020-00359-2","article-title":"Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"10","author":"J\u00f6rg","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib292","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jdv.12419","article-title":"Recurrence of drug-induced reactions in DRESS patients","volume":"29","author":"Picard","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib293","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000458725","article-title":"Multiple drug hypersensitivity","volume":"172","author":"Pichler","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib294","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/all.14146","article-title":"The role of drug, dose, and the tolerance\/intolerance of new drugs in multiple drug hypersensitivity syndrome","volume":"75","author":"J\u00f6rg","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.02.072_bib295","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cod.13462","article-title":"Hypersensitivity to antibiotics in drug reaction with eosinophilia and systemic symptoms (DRESS) from other culprits","volume":"82","author":"Santiago","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2023.02.072_bib296","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4103\/idoj.IDOJ_786_20","article-title":"Autoimmune diseases, end organ dysfunction and adverse drug reaction following drug reaction with eosinophilia and systemic symptoms (DRESS): a retrospective cohort study","volume":"12","author":"Sasidharanpillai","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaad.2023.02.072_bib298","doi-asserted-by":"crossref","DOI":"10.5070\/D32512046688","article-title":"Characteristics of patients hospitalized for drug reaction with eosinophilia and systemic symptoms (DRESS) at a level 1 trauma center","volume":"25","author":"Nguyen","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2023.02.072_bib299","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/ijdvl.IJDVL_482_17","article-title":"Predictors of disease severity in drug reaction with eosinophilia and systemic symptoms","volume":"85","author":"Sasidharanpillai","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2023.02.072_bib300","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1111\/jdv.17838","article-title":"Purpura as an indicator of severity in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: evidence from a 49-case series","volume":"36","author":"Takei","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.072_bib301","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jaip.2019.05.047","article-title":"Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions","volume":"7","author":"Park","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib302","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4168\/aair.2014.6.3.216","article-title":"Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome","volume":"6","author":"Kim","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaad.2023.02.072_bib303","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000354918","article-title":"Clinical features and prognostic factors in severe cutaneous drug reactions","volume":"162","author":"Yang","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib304","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bcp.13096","article-title":"Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital","volume":"83","author":"Ram\u00edrez","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.072_bib305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib306","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1684\/ejd.2017.3211","article-title":"Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"28","author":"Yang","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib307","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjd.12081","article-title":"Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases","volume":"168","author":"Walsh","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib308","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/cup.13713","article-title":"Interface dermatitis as an indicator of hepatic involvement in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"47","author":"Sasidharanpillai","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2023.02.072_bib309","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib310","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib311","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2004.06.023","article-title":"Severe sialadenitis: a new complication of drug reaction with eosinophilia and systemic symptoms","volume":"51","author":"Abecassis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib312","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/s10165-004-0316-3","article-title":"An infant with \u03b3-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second \u03b3-globulin treatment","volume":"14","author":"Miyamae","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib313","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1345\/aph.1G105","article-title":"Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease","volume":"39","author":"Chao","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2023.02.072_bib314","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2332\/allergolint.L-07-09","article-title":"Does drug-induced hypersensitivity syndrome elicit bullous pemphigoid?","volume":"57","author":"Kijima","year":"2008","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.072_bib315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000187619","article-title":"Systemic lupus erythematosus presenting with Kikuchi-Fujimoto's disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of Epstein-Barr virus reactivation","volume":"218","author":"Aota","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.02.072_bib316","doi-asserted-by":"crossref","first-page":"E2277","DOI":"10.1210\/jc.2012-2054","article-title":"High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome","volume":"97","author":"Onuma","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2023.02.072_bib317","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cei.12704","article-title":"Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic\/spontaneous urticaria (CIU)","volume":"183","author":"Dreyfus","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2023.02.072_bib318","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/0019-5154.177781","article-title":"Alopecia areata and vitiligo as a long-term sequelae of drug reaction with eosinophilia and systemic symptoms syndrome","volume":"61","author":"Iskandarli","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib319","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.14625","article-title":"Vitiligo: a potential autoimmune sequela of DRESS syndrome","volume":"175","author":"Lonowski","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib320","article-title":"A mysterious DRESS case: autoimmune enteropathy associated with DRESS syndrome","volume":"2017","author":"Adike","year":"2017","journal-title":"Case Rep Gastrointest Med"},{"key":"10.1016\/j.jaad.2023.02.072_bib321","doi-asserted-by":"crossref","first-page":"492","DOI":"10.47102\/annals-acadmedsg.V47N11p492","article-title":"Relapsing course of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by alopecia universalis and vitiligo","volume":"47","author":"Lian","year":"2018","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.jaad.2023.02.072_bib322","article-title":"Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome","volume":"2018","author":"Morita","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.072_bib323","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/imj.14630","article-title":"Aplastic anaemia following carbamazepine-induced drug reaction with eosinophilia and systemic symptoms syndrome","volume":"49","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2023.02.072_bib324","first-page":"66","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in children","volume":"90","author":"Mori","year":"2019","journal-title":"Acta Biomed"},{"key":"10.1016\/j.jaad.2023.02.072_bib325","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2019.00474","article-title":"Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jaad.2023.02.072_bib326","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/pde.14217","article-title":"Alopecia universalis after drug reaction with eosinophilia and systemic symptoms (Dress)","volume":"37","author":"Hollingsworth","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib327","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/1346-8138.15562","article-title":"Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome","volume":"48","author":"Chiang","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.072_bib328","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaip.2020.07.050","article-title":"Autoimmune hepatitis as a sequelae of oxcarbazepine-induced drug reaction with eosinophilia and systemic symptoms","volume":"9","author":"Droz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.072_bib329","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1515\/jpem-2021-0685","article-title":"Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature","volume":"35","author":"Tempark","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jaad.2023.02.072_bib330","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3345\/cep.2022.00381","article-title":"Graves' disease: an uncommon cause of late sequelae following DRESS (drug reaction with eosinophilia and systemic symptoms)","volume":"65","author":"Tempark","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.jaad.2023.02.072_bib331","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T05:41:19Z","timestamp":1729834879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223024027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":328,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0190962223024027"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.072","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.073","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(24)00154-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}